Terumo Medical has commenced construction on a new manufacturing facility at its site in Caguas, Puerto Rico, to address the rising global demand for its Angio-Seal VCD

The expansion, which includes a 64,000ft² addition and the renovation of an existing 22,000ft² building, represents a $30m investment by the company.

Planned to be completed by 2025, the new facility is expected to enhance Terumo's manufacturing capabilities to meet the growing demand.

The current local operations employ 340 associates.

Terumo said the expansion will increase production capacity and the investment further demonstrates its commitment to its healthcare provider customers across the globe.

Terumo Medical president and CEO Jim Rushworth said: “Terumo is a global leader in entry site management, and our Angio-Seal VCD is an important, highly regarded product within this category.

“Expanding production capacity in Puerto Rico will enable us to meet growing demand. It is yet another strategic investment by Terumo to set us up for future growth, maintain our global success, and better support our healthcare-provider customers and, importantly, their patients.” 

The VCD is designed for use by healthcare providers to ensure rapid and reliable hemostasis following angiographic or interventional procedures.

It is also intended to promote quicker patient mobility and allow same-day discharge.

In December 2023, Terumo launched its new AZUR HydroPack Peripheral Coil System, a soft, universal-shaped platinum and hydrogel coil, in the US.

The US Food and Drug Administration (FDA)-approved system is intended to fill volume behind the Terumo AZUR CX Peripheral Coil System for vessel occlusion and to fill volume inside of the AZUR Framing Coil System for aneurysm occlusion.

Terumo Medical, a subsidiary of Terumo Corporation, is engaged in providing products and services across four divisions: Terumo Health Outcomes (THO), Terumo Interventional Systems (TIS), Terumo Medical Products (TMP), and Terumo Pharmaceutical Solutions (TPS).